Kalocyte Inc.
Baltimore, MD
- UEI
- MJMKM31FM667
- CAGE
- 7KNT0
- Primary NAICS
- 541713 Research and Development in Nanotechnology
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 4 N Martin Luther King Jr Blvd fl 3, Baltimore, MD 21201, USA
- Website
- kalocyte.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $1,799,993 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Production of GLP erythromer for IND enabling animal studies | Defense Advanced Research Projects Agency | $1,799,993 |
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| University Of Maryland, Baltimore | N660012394005 | $227,748 | |
| University Of Maryland, Baltimore | N660012394005 | -$3,848 | |
| University Of Maryland, Baltimore | N660012394005 | $707,991 | |
| University Of Maryland, Baltimore | N660012394005 | $1,199,366 |
Grant awards
Similar vendors
About the company
Kalocyte Inc., a self-certified small disadvantaged biotech company based in Baltimore, Maryland, develops bio-inspired artificial red blood cell substitutes (ErythroMer) for military and civilian trauma resuscitation, competing as a prime contractor (86% of recent awards) and subcontractor on federal R&D programs under full-and-open competitive set-asides with no set-aside restriction.
Kalocyte's capability portfolio centers on the design, development, and manufacturing of ErythroMer, a synthetic oxygen-carrying fluid engineered to address hemorrhagic shock in trauma scenarios. The company operates across the full lifecycle from early research through GLP-compliant manufacturing for regulatory submissions. Recent prime work includes a $1.8 million Other Transaction Agreement awarded by the Defense Advanced Research Projects Agency in August 2025 for production of GLP-grade ErythroMer to support Investigational New Drug animal studies, with performance extending through August 2026 in Baltimore; and a multi-year federal grant from the Defense Health Agency (award date April 2024, completion date April 2027) for optimized lyophilization and reconstitution of ErythroMer, extended by twelve months. Kalocyte subcontracts to the CONCERT (Consortium for Optimized Integration of Bio-artificial Blood Components for Adaptive Resuscitation and Therapy) consortium under Phase 1 base and incremental funding for whole blood analogue pre-clinical development and IND submission support.
Customer concentration splits between the National Institutes of Health National Heart Lung and Blood Institute (four awards, a 57% share of awards), the Defense Advanced Research Projects Agency (two awards, $1.8 million combined potential value), and the Defense Health Agency (one award). The vendor maintains university partnerships with the University of Illinois at Urbana-Champaign for manufacturing and Washington University in St. Louis for in vivo efficacy validation. Three awards totaling $1.8 million in combined potential value reach ultimate completion within the next twenty-four months, representing the recompete window for these programs.
Quick answers
Is Kalocyte Inc. registered in SAM.gov?
Yes. Kalocyte Inc.'s SAM.gov registration is active through March 19, 2027.
What is Kalocyte Inc.'s CAGE code?
Kalocyte Inc.'s CAGE code is 7KNT0, and its Unique Entity ID (UEI) is MJMKM31FM667.
How much has Kalocyte Inc. received in federal contracts?
Federal contracts obligated $1,799,993 to Kalocyte Inc. in fiscal year 2025.
How does Kalocyte Inc. rank among federal contractors?
Kalocyte Inc. ranked #28 in PSC AC15 in FY2025.
What is Kalocyte Inc.'s most recent federal award?
Kalocyte Inc.'s most recent federal contract award is Production of GLP erythromer for IND enabling animal studies (HR00112590241), from Defense Advanced Research Projects Agency, on August 14, 2025.
On GovTribe
See Kalocyte Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors